Choriogonadotropin Alfa
drugOn this page
Also known as ATC CODE G03 GA GONADOTROPINSChoriogonadotropin alphaChoriogonadotropine alfaChoriongonadotropin alfaChorionic gonadotrophin alfaCoriogonadotropina alfaFe-999302OvidrelOvitrelle
Summary
Choriogonadotropin Alfa (CHEMBL1201464) is an approved protein (ATC G03GA08); indicated across 9 conditions including infertility disorder and obesity disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: G03GA08
- Indications: 9 conditions
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201464 |
| Name | Choriogonadotropin Alfa |
| Type | Protein |
| Max phase | 4 |
| ATC | G03GA08 |
Also known as: ATC CODE G03 GA GONADOTROPINS, Choriogonadotropin alfa, Choriogonadotropin alpha, Choriogonadotropine alfa, Choriongonadotropin alfa, Chorionic gonadotrophin alfa, Coriogonadotropina alfa, Fe-999302, Ovidrel, Ovitrelle, CHORIOGONADOTROPIN ALFA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| infertility disorder | 4 | MONDO:0005047 | EFO:0000545 |
| obesity disorder | 4 | MONDO:0011122 | EFO:0001073 |
| primary ovarian failure | 4 | MONDO:0005387 | EFO:0004266 |
| hypogonadism | 4 | MONDO:0002146 | MONDO:0002146 |
| female infertility | 4 | MONDO:0021124 | EFO:0008560 |
| anovulation | 4 | MONDO:0002775 | MONDO:0002775 |
| ovarian hyperstimulation syndrome | 3 | MONDO:0011972 | MONDO:0011972 |
| polycystic ovary syndrome | 2 | MONDO:0008487 | EFO:0000660 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 3 |
| Not specified | 3 |
| EARLY_PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02825290 | PHASE4 | UNKNOWN | Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study |
| NCT03495609 | PHASE4 | COMPLETED | Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers |
| NCT04643925 | PHASE4 | COMPLETED | hCG Priming in Women With Low Ovarian Reserve |
| NCT03440359 | PHASE2/PHASE3 | COMPLETED | Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole |
| NCT05571111 | PHASE2 | WITHDRAWN | Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation |
| NCT07557615 | EARLY_PHASE1 | NOT_YET_RECRUITING | hCG Treatment for Rehabilitation From a TBI |
| NCT05450900 | EARLY_PHASE1 | COMPLETED | Can Biotin Supplementation be Used to Mask hCG Abuse? |
| NCT01205009 | Not specified | UNKNOWN | Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders |
| NCT03540979 | Not specified | UNKNOWN | Endometrial Preparation in Frozen Embryo Transfer Cycles |
| NCT04717752 | Not specified | UNKNOWN | A Randomized Controlled Study of Different Trigger Modes of Antagonist Regimen in Patients With Low Ovarian Reserve |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).